Sitagliptin versus placebo in the treatment of nonalcoholic fatty liver disease: A randomized controlled trial

BACKGROUND & AIMS: Uncontrolled studies show sitagliptin, an oral DPP-4 inhibitor, may improve alanine aminotransferase (ALT) and liver histology in nonalcoholic fatty liver disease (NAFLD) patients. We aimed to compare sitagliptin versus placebo's efficacy in reducing liver fat measured by...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hepatol
Main Authors: Cui, Jeffrey, Philo, Len, Nguyen, Phirum, Hofflich, Heather, Hernandez, Carolyn, Bettencourt, Ricki, Richards, Lisa, Salotti, Joanie, Bhatt, Archana, Hooker, Jonathan, Haufe, William, Hooker, Catherine, Brenner, David A, Sirlin, Claude B, Loomba, Rohit
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5081213/
https://ncbi.nlm.nih.gov/pubmed/27151177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2016.04.021
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados